01861nas a2200301   4500000000100000008004100001260000900042653002700051653002200078653001700100653001900117653001100136653002000147653002900167653001200196653002000208653002300228653002800251653001300279100001500292700001100307700001400318245006900332300001000401490000700411520112700418022001401545       1985                            d  c198510aABO Blood-Group System10aAntibodies, Viral10aErythrocytes10aHemagglutinins10aHumans10aImmunodiffusion10aInfectious Mononucleosis10aleprosy10aMercaptoethanol10aMultiple Sclerosis10aNewcastle disease virus10aSyphilis1 aPowell J A1 aKano K1 aMilgrom F00aAntibodies to Newcastle disease virus in various human diseases.  a331-50 v763 a<p>Sera of patients with infectious mononucleosis (IM) and various other diseases were studied for agglutinins against Newcastle disease virus (NDV)-modified human group O red blood cells (NDVO) and antibodies to the NDV preparations. In agreement with previous studies, the NDVO antibodies are found in a wide variety of diseases in addition to IM, including Japanese IM-like syndrome (22%), syphilis (24%), lepromatous leprosy (30%), systemic lupus erythematosus (29%), multiple sclerosis (18%) and cancer (17%); these antibodies were also found in patients with renal allografts (29%). It was also noted that the Victoria (VIC), Roakin and Herts strains, but not B1 strain of NDV are active in the NDVO agglutination, and VIC and Roakin strains, but not B1 strain in the immunodiffusion. Immunodiffusion and enzyme immunoassay with various preparations of the VIC strain revealed that the major antigen(s) of the virus under study is carried by the hemagglutinin-neuraminidase (H-N) glycoproteins. The H-N molecule was also shown to be able to modify human erythrocytes for the agglutination by the pathologic sera.</p>  a0020-5915